Company

Novo Nordisk

Official Name: Novo Nordisk A/S

Headquarters: Bagsvaerd, Denmark

Founded: December 21, 1923

Employees: 47,792

CEO: Mr. Lars Fruergaard Jorgensen

OMXC: NOVO.B +0.41%

Market Cap

kr.3.117 Trillion

DKK as of Jan. 1, 2024

US$461.52 Billion

Market Cap History

Company Description

Novo Nordisk is a global healthcare company involved in the research, development, manufacture, and marketing of pharmaceutical products. It operates through two segments: Diabetes and Obesity care, providing products for insulins, GLP-1, oral antidiabetic products, obesity, and other chronic diseases; and Biopharm, offering products for haemophilia, growth disorders, and hormone replacement therapy.

Novo Nordisk market capitalization over time

Evolution of Novo Nordisk A/S market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Novo Nordisk A/S

Detailed Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Top 1-year algo backtest: +298.72%

$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Product & Services

Ozempic, Ryzodeg, Victoza, NovoEight, Activella, Novolin, Levemir, NovoSeven, Norditropin, Tresiba, Xultophy, NovoRapid, Fiasp, Saxenda

Key People

Helge Lund (Chairman) Lars Fruergaard Jørgensen (President & CEO)

Financials

Revenue: DKK 140.80 billion (2021)

Operating income: DKK 52.483 billion (2019)

Net income: DKK 38.951 billion (2019)


Total assets: DKK 125.612 billion (2019)

Total equity: DKK 57.593 billion (2019)

Details

Headquarters:

Novo Alle 1

Bagsvaerd, 2880

Denmark

Phone: 45 44 44 88 88